Search

Certara Inc

Open

SectorHealthcare

6.86 -1.58

Overview

Share price change

24h

Current

Min

6.77

Max

6.99

Key metrics

By Trading Economics

Income

-2.9M

-8.8M

Sales

3.3M

107M

P/E

Sector Avg

100.714

60.149

EPS

-0.06

Profit margin

-8.196

Employees

1,515

EBITDA

-16M

16M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+12.41% upside

Dividends

By Acuity

Next Earnings

4 Aug 2026

Market Stats

By TradingEconomics

Market Cap

258M

1.1B

Previous open

8.44

Previous close

6.86

News Sentiment

By Acuity

19%

81%

32 / 340 Healthcare

Certara Inc Chart

Past performance is not a reliable indicator of future results.

Related News

20 Jul 2026, 19:31 UTC

News

Certara Inc partners with NVIDIA to enhance its AI biosimulation platform. Shares are higher, reflecting positive market sentiment around the collaboration.

Peer Comparison

Price change

Certara Inc Forecast

Price Target

By TipRanks

12.41% upside

12 Months Forecast

Average 7.79 USD  12.41%

High 10 USD

Low 6 USD

Based on 9 Wall Street analysts offering 12 month price targets forCertara Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

3

Buy

6

Hold

0

Sell

Sentiment

By Acuity

32 / 340 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat